within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD05_Triazolam;

model Triazolam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.44,
    Cl = 1.7500000000000002e-06,
    adminDuration = 600,
    adminMass = 0.5 / 1000000,
    adminCount = 1,
    Vd = 0.0013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005666666666666667,
    Tlag = 9.6,
    Vdp = 0.0005200000000000001,
    k12 = 6.4166666666666665e-06,
    k21 = 6.4166666666666665e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Triazolam</td></tr><tr><td>ATC code:</td><td>N05CD05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Triazolam is a short-acting benzodiazepine used primarily for the treatment of insomnia. It is indicated for short-term management of sleep disorders and is not recommended for long-term use due to dependence and tolerance risks. Triazolam is still available in some countries but its use is restricted or discontinued in others due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (male and female), age 19-38 years, after a single oral dose.</p><h4>References</h4><ol><li><p>Friedman, H, et al., &amp; Shader, RI (1986). Population study of triazolam pharmacokinetics. <i>British journal of clinical pharmacology</i> 22(6) 639–642. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1986.tb02951.x\">10.1111/j.1365-2125.1986.tb02951.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3567010/\">https://pubmed.ncbi.nlm.nih.gov/3567010</a></p></li><li><p>Ozdemir, V, et al., &amp; Naranjo, CA (1996). Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?. <i>Clinical pharmacokinetics</i> 31(5) 372–385. DOI:<a href=\"https://doi.org/10.2165/00003088-199631050-00004\">10.2165/00003088-199631050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9118585/\">https://pubmed.ncbi.nlm.nih.gov/9118585</a></p></li><li><p>Perucca, E, et al., &amp; Fuseau, E (2008). Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. <i>Epilepsia</i> 49(7) 1123–1141. DOI:<a href=\"https://doi.org/10.1111/j.1528-1167.2008.01665.x\">10.1111/j.1528-1167.2008.01665.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18503564/\">https://pubmed.ncbi.nlm.nih.gov/18503564</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CD05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Triazolam;
